arrow
T

Takuto Takahashi

Dana-Farber Cancer Institute and Boston Children's Hospital
H指数:11
被引数:367

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL

异基因HSCT结局及defibrotide预防在inotuzumab治疗后儿童B-ALL患者中继发OS的影响

2026-07-200
OA
Corrigendum to “Effects of total body irradiation on hematopoietic cell transplantation outcomes in pediatric acute myeloid leukemia with prior central nervous system involvement” Journal title: Transplantation and Cellular Therapy (Volume 30, Issue 8, August 2024, Pages 812.e1-812.e11)

更正:“中枢神经系统受累的儿童急性髓系白血病造血细胞移植结局中全身照射的影响”期刊名称:Transplantation and Cellular Therapy(卷30,第8期,2024年8月,第812.e1-812.e11页)

2026-04-020
PRE
Corrigendum to "Umbilical cord blood reduced relapse but increased non-relapse mortality compared to matched unrelated donor transplantation in pediatric AML with active disease: A CIBMTR 2008-2017 analysis of donor source and residual disease" Transplantation and Cellular Therapy (Volume 31, Issue 4, April 2025, Pages 261.e1-261.e15)

勘误:"脐带血降低了复发率,但与匹配无关供者移植相比增加了非复发死亡率:儿科AML活动性疾病供者来源及残留病灶分析(CIBMTR 2008-2017年)",《移植与细胞治疗》(第31卷,第4期,2025年4月,第261.e1-261.e15页)

2026-04-010
PRE
Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial
2026-01-010
OAAI
Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients

年龄对儿科造血细胞移植受者移植物抗宿主病和总生存期的影响

2025-12-160
OAAI
The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities
2025-02-010
PRE
Efficacy and Safety of Eltrombopag Added to Rabbit Anti-Human Thymocyte Globulin plus Cyclosporine in Aplastic Anemia: Results from a Prospective Multicenter Phase II Study

Eltrombopag联合兔抗人胸腺细胞球蛋白与环孢素治疗再生障碍性贫血的疗效与安全性:一项前瞻性多中心II期研究的结果

BLOOD
IF23.1
2024-11-050
PRE